Vaccine Process Development and Manufacturing
Single-Use Technologies and Associated Services Addressing Process Development and Productions Needs of Vaccine Manufacturers
Vaccination is one of the great inventions of all time. Vaccines have saved countless lives and improved the health of people all over the world.
Sartorius technology supports the production of traditional vaccines and emerging technologies such as recombinant vaccines. This is helping the industry to address both global endemic diseases and less predictable, but potentially devastating, localized outbreaks.
More than ever, people around the world need access to vaccines produced to rigorous standards of quality but at low cost. Flexible production facilities are needed that will allow capacity to be modulated easily. Increasingly vaccine manufacturers are seeking to construct and operate these facilities in locations across the globe to shorten delivery times and cold chain supply networks.
Solutions to Fight the Coronavirus Outbreak
The current Coronavirus outbreak is creating serious health and economic impact in the entire world as it spreads at unprecedented speed. Many private and public companies, and funding organizations are putting a significant amount of effort to develop a vaccine that could stop the spreading of the virus, thus saving thousands of lives. In such times speed is of essence and vaccine manufacturers will be looking for agile and responsive partners like Sartorius.
Preparing for the next pandemic will take multiple vaccine platforms, including traditional and emerging technologies. Our interactive process flow diagrams allow you to explore the challenges, and Sartorius’ solutions, for:
- Virus-based vaccines, including inactivated viral vaccines and live-attenuated viral vaccines
- Viral vector vaccines, based on enveloped and non-enveloped vectors, as well as other commonly used vectors
- Nucleic acid vaccines, either plasmid DNA or a messenger RNA molecule coding for a disease-specific antigen (such as the mRNA vaccine for COVID-19 coding for the spike protein on the SARS-CoV-2 virus)
- Recombinant protein vaccines, which consist of viral or bacterial antigen produced using recombinant technology
Recommendation for Vaccine Manufacturers Considering Implementing Production Solutions
Amélie Boulais, Vaccine Platform Marketing Manager at Sartorius Stedim Biotech
“Customers should not hesitate to explore innovative new processing solutions that can have an enormous impact on the productivity of the final process. Early stage development scientists now have access to bioprocessing technologies that can then be scaled-up into cGMP production. There are many good high-throughput screening tools and scale-down models for process development these days. Sartorius Process Development Consultants can help you develop an overall strategy for the design and implementation of your new vaccine process and our application scientists will assist you in optimizing individual steps."
ABL Europe’s New Production Facility for the GMP Manufacture of Viral VectorsPDF | 7.6 MB
Accelerated Development, Manufacturing and Monitoring of Viral VectorsPDF | 3.5 MB
Sartorius has presented its capacity to support the industry to develop and manufacture a COVID-19 vaccine in a series of webinars. From processes overviews to deep dives into specific technologies and Services, listen to our experts and feel free to contact us to engage in further discussions.